Orexigen Beefs Up Management

11/23/09Follow @xconomy

Orexigen Therapeutics (NASDAQ: OREX), the San Diego-based developer of obesity drugs, said today it has added four new executives to its management team. Dawn Viveash is the new head of global regulatory affairs; Suzanne McDonald will be responsible for managed markets and government affairs; Preston Klassen will be the head of the global Contrave program; and Whedy Wang is the new head of global biomedical information. CEO Mike Narachi explained his plan for re-inventing the company, and some of the other new managers he brought in earlier this year, in a feature back in September.

By posting a comment, you agree to our terms and conditions.